REG - Redx Pharma plc - Result of AGM and Directorate change

Redx PharmaAnnouncement

02/03/2021 12:40

RNS Number : 8923Q
  
Redx Pharma plc
  
02 March 2021
  
 

 
 
REDX PHARMA PLC
("Redx" or "the Company")
 
Result of Annual General Meeting and Directorate change
 
Alderley Park, 2 March 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that its Annual General Meeting was held at 11.00 am on 2 March 2021, with all resolutions passed by substantial majorities.  
 
The table below sets out the details of the votes put to shareholders
 



Resolution numbe


Resolution name


Number of votes for & discretionary


% of votes for & discretionary


Number of votes against


% of votes against


% of votes witheld


Total votes cast (including withheld)




1


Receive the Company's annual accounts


247,031,884


94.79%


13,571,429


5.21%


0.00%


260,604,013




2


Re-appoint RSM as auditors


260,597,840


100%


200


0.00%


0.00%


260,604,013




3


Elect Sarah Gordon Wild as a director


260,597,840


100%


200


0.00%


0.00%


260,604,013




4


Elect Dr Thomas Burt as a director


260,597,840


100%


200


0.00%


0.00%


260,604,013




5


Re-elect Lisa Anson as a director


260,603,513


100%


0


0.00%


0.00%


260,604,013




6


Re-elect Dr Bernd Kirschbaum as a director


260,598,040


100%


0


0.00%


0.00%


260,604,013




7


Re-elect Peter Presland as a director


260,603,513


100%


0


0.00%


0.00%


260,604,013




8


Authorise the directors to allot shares


260,594,551


100%


1,686


0.00%


0.00%


260,604,013




9


Disapply pre-emption rights


260,594,551


100%


2,389


0.00%


0.00%


260,604,013



 
The Chairman, Iain Ross provided the following update:
 
"As the Company continues to progress its pipeline and expand its operations,  the Board has reviewed its composition and that of the executive leadership  team. As a result, a search for a US based Chief Financial Officer has been initiated. James Mead will continue in his role as Chief Financial Officer until a new appointment has been made at which point Dr Mead will assume the role of Chief Operating Officer. In conjunction with these changes,  Dr Mead will step down from the Board with immediate effect and will cease to be a Director of the Company. Going forward, the Board will therefore consist of five non-executive directors and one executive director, the CEO. Finally on a personal basis I would like to thank James for his contribution to the Board over the last two years, and his ongoing commitment as a member of the executive management team going forward."
 
 



For further information, please contact:


















Redx Pharma Plc 


T: +44 1625 469 918




Iain Ross, Chairman
Lisa Anson, Chief Executive
James Mead, Chief Financial Officer


















SPARK Advisory Partners (Nominated Adviser)


 T: +44 203 368 3550




Matt Davis/Adam Dawes


















WG Partners LLP (Broker)


T: +44 20 3705 9330




Claes Spång/Chris Lee/David Wilson




























FTI Consulting


T: +44 20 3727 1000




Simon Conway/Ciara Martin








 
 







 
About Redx Pharma Plc 
 
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
 
The Company's  core capability  of converting  medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
RAGUUOURANUORAR